Morgan Stanley’s Loxo Oncology, Inc LOXO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-74,524
Closed -$10.4M 6866
2018
Q4
$10.4M Sell
74,524
-13,489
-15% -$2.05M ﹤0.01% 2079
2018
Q3
$15M Sell
88,013
-44,394
-34% -$7.46M ﹤0.01% 1960
2018
Q2
$23M Buy
132,407
+58,879
+80% +$8.85M 0.01% 1513
2018
Q1
$8.48M Buy
73,528
+936
+1% +$99.6K ﹤0.01% 2500
2017
Q4
$6.11M Buy
72,592
+14,985
+26% +$1.25M ﹤0.01% 2884
2017
Q3
$5.31M Sell
57,607
-29,587
-34% -$2.3M ﹤0.01% 2905
2017
Q2
$6.99M Buy
87,194
+55,869
+178% +$3.1M ﹤0.01% 2513
2017
Q1
$1.32M Sell
31,325
-13,028
-29% -$537K ﹤0.01% 4173
2016
Q4
$1.42M Buy
44,353
+38,406
+646% +$984K ﹤0.01% 4196
2016
Q3
$155K Buy
5,947
+379
+7% +$9.92K ﹤0.01% 5117
2016
Q2
$130K Buy
5,568
+3,752
+207% +$93.4K ﹤0.01% 5125
2016
Q1
$49K Sell
1,816
-14,861
-89% -$311K ﹤0.01% 5618
2015
Q4
$475K Buy
16,677
+16,324
+4,624% +$438K ﹤0.01% 4579
2015
Q3
$6K Buy
353
+67
+23% +$1.31K ﹤0.01% 6360
2015
Q2
$6K Sell
286
-3,809
-93% -$52.1K ﹤0.01% 6404
2015
Q1
$51K Buy
4,095
+3,593
+716% +$44.8K ﹤0.01% 5788
2014
Q4
$6K Sell
502
-5,129
-91% -$59.8K ﹤0.01% 6311
2014
Q3
$74K Buy
+5,631
New +$73.1K ﹤0.01% 5594

Other funds holding LOXO

Morgan Stanley's LOXO Position: Q1 2019 in Review

Morgan Stanley sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 74,524 shares — an estimated $10.4M sold.

Morgan Stanley first reported a position in LOXO in Q3 2014 and held it in 18 quarters. The position peaked at $23M in Q2 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.

  • Morgan Stanley reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
  • Morgan Stanley sold 74,524 Loxo Oncology, Inc shares in Q1 2019, an estimated $10.4M.
  • Morgan Stanley first reported a position in Loxo Oncology, Inc in Q3 2014 and held it in 18 quarters.
  • Morgan Stanley's Loxo Oncology, Inc position peaked at $23M in Q2 2018.
  • 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.

Based on Morgan Stanley's 13F filing for Q1 2019, filed 15 May 2019.